Intelligence Feed event · Policy · 2026-09-12

    Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms

    Question

    Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms

    Direct answer

    Liquidia Corporation has scaled its lead dry-powder inhaled therapy Yutrepia to more than 5,000 patients as of July 2026. However, equity valuation has faced downward pressure, declining 13.9% over the past month. The market discount reflects ongoing patent litigation with incumbent United Therapeutics (UTHR) alongside elevated R&D spending and single-asset revenue concentration in pulmonary hypertension indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/liquidia-surpasses-5-000-yutrepia-patients-as-united-therapeutics-litigation-loo-85a6b7

    POLICY
    Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms
    Liquidia Corporation has scaled its lead dry-powder inhaled therapy Yutrepia to more than 5,000 patients as of July 2026. However, equity valuation has faced downward pressure, declining 13.9% over the past month. The market discount reflects ongoing patent litigation with incumbent United Therapeutics (UTHR) alongside elevated R&D spending and single-asset revenue concentration in pulmonary hypertension indications.
    LQDAUTHR
    Impact
    64
    SEP 12
    SIG
    85%
    LQDAUTHR
    Liquidia surpasses 5,000 Yutrepia patients as United Therapeutics litigation looms
    Liquidia Corporation has scaled its lead dry-powder inhaled therapy Yutrepia to more than 5,000 patients as of July 2026. However, equity valuation has faced downward pressure, declining 13.9% over the past month. The market discount reflects ongoing patent litigation with incumbent United Therapeutics (UTHR) alongside elevated R&D spending and single-asset revenue concentration in pulmonary hypertension indications.
    → Litigation risk over inhaled treprostinil IP threatens Yutrepia market access, discounting LQDA valuation despite 5,000-patient adoption.
    Impact
    Liquidia Corporation has scaled its lead dry-powder inhaled therapy Yutrepia to more than 5,000 patients as of July 2026. However, equity valuation has faced downward pressure, declining 13.9% over the past month. The market discount reflects ongoing patent litigation with incumbent United Therapeutics (UTHR) alongside elevated R&D spending and single-asset revenue concentration in pulmonary hypertension indications.
    Affected
    LQDAUTHR
    Transmission
    Litigation risk over inhaled treprostinil IP threatens Yutrepia market access, discounting LQDA valuation despite 5,000-patient adoption.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LQDApatent litigation risk discounting commercial revenue growthMixed1-3mOver 5,000 patients started on Yutrepia vs ongoing patent litigation with UTHR
    UTHRcompetitive market-share defense in pulmonary arterial hypertensionMixed1-3mOngoing patent litigation with Liquidia over treprostinil market share

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month